Edico Genome operates in the genomic testing and sequencing industry, focusing on providing advanced solutions for oncology. The company serves healthcare providers, research institutions, and pharmaceutical companies by offering comprehensive genomic profiling from both blood and tissue samples. Edico Genome's business model revolves around selling high-precision sequencing instruments, reagents, and software tools that enable accurate measurement and analysis of genetic data. Revenue is generated through the sale of these products, as well as through partnerships and collaborations that expand patient access to genomic testing. The company aims to transform cancer treatment by offering tools that predict cancer risk, identify targets for breast cancer, and facilitate liquid biopsies. Edico Genome's market includes the broader healthcare and life sciences sectors, with a particular emphasis on oncology research and personalized medicine.

Keywords: genomic testing, oncology, sequencing technology, cancer risk prediction, personalized treatment, healthcare providers, research institutions, pharmaceutical companies, liquid biopsies, genomic profiling.